Both Sanofi and Orano Med are part of the Paris Saclay cancer cluster and are committed to supporting the France 2030 plan's ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi ...

PARIS--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an ...

The new entity will operate under the brand of Orano Med, a subsidiary of Orano Group. Sanofi already has a relationship with Orano Med. Last month, the Paris-based pharmaceutical giant licensed ...

Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their ...

Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a ...